WuXi AppTec Advanced Therapies will manufacture Nohla’s cell therapies at their Philadelphia Navy Yard campus, which features over 220,000 square feet of GMP compliant manufacturing space.
Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignancies and other critical diseases, and WuXi AppTec Advanced Therapies, a streamlined Contract Development and Manufacturing Organization (CDMO), have entered into a commercial agreement for production of Nohla’s NLA101, a universal donor, ex vivo expanded hematopoietic stem and progenitor cell product.
“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and cGMP manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy program, NLA101,” said Katie Fanning, President and Chief Executive Officer of Nohla.
“We are very pleased to enter into this manufacturing partnership with Nohla,” said Felix Hsu, Senior Vice President and Head of WuXi AppTec Advanced Therapies. “With our integrated manufacturing services, we believe we can bring speed and reliability to the manufacturing needs of Nohla and support the rapid advance of their clinical timelines. We are committed to helping our partners deliver these innovative therapies to patients and the market sooner.”
WuXi AppTec Advanced Therapies will manufacture Nohla’s universal cell therapies in their 55,000 square foot commercial manufacturing facility for cell therapies, one of three facilities in the Philadelphia Navy Yard supporting the development, manufacturing, and quality control testing of cell and gene therapies.